
    
      Evaluate the safety and efficacy of Myfortic in combination with tacrolimus and
      anti-thymocyte globulin in an early corticosteroid withdrawal protocol. Secondary objective
      is to determine the pharmacokinetic-pharmacodynamic profile of Myfortic in a corticosteroid
      withdrawal protocol.
    
  